Aafia Chaudhry

Dr. Aafia Chaudhry is a physician executive and angel investor who combines deep clinical expertise with senior pharmaceutical industry leadership. She holds an MD, an Executive MBA from the Samuel Curtis Johnson Graduate School of Management at Cornell University, and an MS in Healthcare Leadership from Weill Cornell Graduate School of Medical Sciences (Class of 2020). Her dual medical and business training positions her uniquely at the intersection of clinical science and healthcare business strategy.

Professionally, Dr. Chaudhry serves as Vice President and Global Program Head for Hematology-Oncology at Regeneron Pharmaceuticals, where she leads strategic program direction in immuno-oncology, including the clinical development of bispecific antibodies such as odronextamab for the treatment of B-cell non-Hodgkin lymphoma. Prior to Regeneron, she held senior leadership roles at Novocure, where she was one of only a few individuals with a medical background in senior leadership and was credited as instrumental in the company's growth. She has also held a position at Cisco.

Outside of her corporate roles, Dr. Chaudhry operates as an angel investor through Katabbia Advisors, focusing on seed-stage opportunities. She has contributed biotech and pharmaceutical industry analysis as a writer for TheStreet (2013-2014) and has published academic research on social media use in scientific and pharmaceutical conferences. She is a strong advocate for mentorship, pay equity, and women's advancement in healthcare leadership.

Dr. Chaudhry invests at the seed stage through Katabbia Advisors. While her specific portfolio companies have not been publicly disclosed, her professional background and expertise strongly suggest a focus on:

Her investment approach likely draws on her philosophy that success is built by assembling and leading high-performing teams, a principle she has articulated in her professional mentorship work.

• Healthcare and life sciences startups -- particularly those in oncology, immuno-oncology, and novel therapeutics
• Biotech and pharmaceutical innovation -- leveraging her deep domain expertise as a physician executive in drug development
• Healthcare technology and digital health -- informed by her MBA/MS in Healthcare Leadership and her research on digital communication in medicine
• Early-stage companies where clinical and regulatory insight from a physician-investor adds strategic value beyond capital